Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds.

Mendoza Marí Y, Fernández Mayola M, Aguilera Barreto A, García Ojalvo A, Bermúdez Alvarez Y, Mir Benítez AJ, Berlanga Acosta J

Plastic surgery international20 Apr 2016Cited by 3 (Europe PMC)

PMID27200188PMCIDPMC4854984DOI10.1155/2016/4361702PepBankPUB-27200188

Download PDF PubMedAsk about this study

Jump to 7 results

Summary

In addition to its cytoprotective effects, growth hormone-releasing peptide 6 (GHRP-6) proved to reduce liver fibrotic induration. CD36 as one of the GHRP-6 receptors appears abundantly represented in cutaneous wounds granulation tissue. The healing response in a scenario of CD36 agonistic stimulation had not been previously investigated. Excisional full-thickness wounds (6 mmØ) were created in the dorsum of Wistar rats and topically treated twice a day for 5 days. The universal model of rabbit's ears hypertrophic scars was implemented and the animals were treated daily for 30 days. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL. Wounds response characterization included closure dynamic, RT-PCR transcriptional profile, histology, and histomorphometric procedures. The rats experiment indicated that GHRP-6 pharmacodynamics involves attenuation of immunoinflammatory mediators, their effector cells, and the reduction of the expression of fibrotic cytokines. Importantly, in the hypertrophic scars rabbit's model, GHRP-6 intervention dramatically reduced the onset of exuberant scars by activating PPARγ and reducing the expression of fibrogenic cytokines. GHRP-6 showed no effect on the reversion of consolidated lesions. This evidence supports the notion that CD36 is an active and pharmacologically approachable receptor to attenuate wound inflammation and accelerate its closure so as to improve wound esthetic.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats with full-thickness wounds, GHRP‑6 attenuated immunoinflammatory mediators.
In plain wordsIn rats with wounds, GHRP‑6 reduced inflammatory mediators.
Peptide
GHRP-6
Outcome
DecreaseImmunoinflammatory mediators
Study
ratn: not reported in source
Wistar rat full-thickness wounds
Outcome group
Inflammation markers · Skin and wound
Studied dose
400 μg/mL · topical · 5 daysAs given in this study (rat).
Source sentences
Summary
The rats experiment indicated that GHRP-6 pharmacodynamics involves attenuation of immunoinflammatory mediators, their effector cells, and the reduction of the expression of fibrotic cytokines.
2 context sentences(design, population, supporting numbers)
Summary · context
Excisional full-thickness wounds (6 mmØ) were created in the dorsum of Wistar rats and topically treated twice a day for 5 days.
Summary · context
Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL.
Show in the study text Report a problemFND-2720018801
02AnimalAnimal study (in vivo)Mechanism
In rats with full-thickness wounds, GHRP‑6 attenuated inflammatory effector cells.
In plain wordsIn rats with wounds, GHRP‑6 reduced inflammatory effector cells.
Peptide
GHRP-6
Outcome
DecreaseInflammatory effector cells
Study
ratn: not reported in source
Wistar rat full-thickness wounds
Outcome group
Immune response · Skin and wound
Studied dose
400 μg/mL · topical · 5 daysAs given in this study (rat).
Source sentences
Summary
The rats experiment indicated that GHRP-6 pharmacodynamics involves attenuation of immunoinflammatory mediators, their effector cells, and the reduction of the expression of fibrotic cytokines.
2 context sentences(design, population, supporting numbers)
Summary · context
Excisional full-thickness wounds (6 mmØ) were created in the dorsum of Wistar rats and topically treated twice a day for 5 days.
Summary · context
Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL.
Show in the study text Report a problemFND-2720018802
03AnimalAnimal study (in vivo)Mechanism
In rats with full-thickness wounds, GHRP‑6 reduced fibrotic cytokine expression.
In plain wordsIn rats with wounds, GHRP‑6 reduced fibrotic cytokine expression.
Peptide
GHRP-6
Outcome
DecreaseFibrotic cytokine expression
Study
ratn: not reported in source
Wistar rat full-thickness wounds
Outcome group
Wound healing · Skin and wound
Studied dose
400 μg/mL · topical · 5 daysAs given in this study (rat).
Source sentences
Summary
The rats experiment indicated that GHRP-6 pharmacodynamics involves attenuation of immunoinflammatory mediators, their effector cells, and the reduction of the expression of fibrotic cytokines.
2 context sentences(design, population, supporting numbers)
Summary · context
Excisional full-thickness wounds (6 mmØ) were created in the dorsum of Wistar rats and topically treated twice a day for 5 days.
Summary · context
Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL.
Show in the study text Report a problemFND-2720018803
04AnimalAnimal study (in vivo)Efficacy outcome
In rabbits with the hypertrophic scar model, GHRP‑6 reduced the onset of exuberant scars.
In plain wordsIn rabbits, GHRP‑6 reduced excessive scar formation.
Peptide
GHRP-6
Outcome
DecreaseExuberant scar onset
Study
rabbitn: not reported in source
ear hypertrophic scars
Outcome group
Wound healing · Skin and wound
Studied dose
400 μg/mL · topical · 30 daysAs given in this study (rabbit).
Source sentences
Summary
Importantly, in the hypertrophic scars rabbit's model, GHRP-6 intervention dramatically reduced the onset of exuberant scars by activating PPARγ and reducing the expression of fibrogenic cytokines.
1 context sentence(design, population, supporting numbers)
Summary · context
The universal model of rabbit's ears hypertrophic scars was implemented and the animals were treated daily for 30 days. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL.
Show in the study text Report a problemFND-2720018804
05AnimalAnimal study (in vivo)Mechanism
In rabbits with the hypertrophic scar model, GHRP‑6 activated PPARγ.
In plain wordsIn rabbits, GHRP‑6 activated PPARγ in the hypertrophic scar model.
Peptide
GHRP-6
Outcome
IncreasePPARγ activation
Study
rabbitn: not reported in source
ear hypertrophic scars
Outcome group
Receptor activity and mechanism · Skin and wound
Studied dose
400 μg/mL · topical · 30 daysAs given in this study (rabbit).
Source sentences
Summary
Importantly, in the hypertrophic scars rabbit's model, GHRP-6 intervention dramatically reduced the onset of exuberant scars by activating PPARγ and reducing the expression of fibrogenic cytokines.
1 context sentence(design, population, supporting numbers)
Summary · context
The universal model of rabbit's ears hypertrophic scars was implemented and the animals were treated daily for 30 days. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL.
Show in the study text Report a problemFND-2720018805
06AnimalAnimal study (in vivo)Mechanism
In rabbits with the hypertrophic scar model, GHRP‑6 reduced fibrogenic cytokine expression.
In plain wordsIn rabbits, GHRP‑6 reduced fibrogenic cytokine expression.
Peptide
GHRP-6
Outcome
DecreaseFibrogenic cytokine expression
Study
rabbitn: not reported in source
ear hypertrophic scars
Outcome group
Wound healing · Skin and wound
Studied dose
400 μg/mL · topical · 30 daysAs given in this study (rabbit).
Source sentences
Summary
Importantly, in the hypertrophic scars rabbit's model, GHRP-6 intervention dramatically reduced the onset of exuberant scars by activating PPARγ and reducing the expression of fibrogenic cytokines.
1 context sentence(design, population, supporting numbers)
Summary · context
The universal model of rabbit's ears hypertrophic scars was implemented and the animals were treated daily for 30 days. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL.
Show in the study text Report a problemFND-2720018806
07AnimalAnimal study (in vivo)Efficacy outcome
In the rabbit scar model, GHRP‑6 did not reverse consolidated lesions.
In plain wordsIn rabbits, GHRP‑6 did not reverse established scar lesions.
Peptide
GHRP-6
Outcome
No significant changeReversion of consolidated lesions
Study
rabbitn: not reported in source
consolidated scar lesions
Outcome group
Wound healing · Skin and wound
Studied dose
400 μg/mL · topical · 30 daysAs given in this study (rabbit).
Source sentences
Summary
GHRP-6 showed no effect on the reversion of consolidated lesions.
1 context sentence(design, population, supporting numbers)
Summary · context
The universal model of rabbit's ears hypertrophic scars was implemented and the animals were treated daily for 30 days. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL.
Show in the study text Report a problemFND-2720018807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.